A recent Pharmalot roundup highlights reporting that one of Rhode Island’s most-wanted fugitives, identified as Ronald Fischer, reportedly worked for roughly two decades in the biotech sector under the assumed name Richard Graydon. According to the coverage cited, Fischer — a former doctor with a past sexual assault conviction who spent two decades on the run — secured positions that included at least one full-time role at a biotech company and contractual arrangements with at least two large drugmakers.
The report indicates that much of the résumé submitted under the alias was fabricated, but the falsified details nonetheless aligned with common hiring filters: academic credentials, board certification, and years of leadership experience linked to cancer drug development. That combination reportedly made the alias attractive to industry recruiters and hiring managers, helping the individual pass initial vetting.
The story raises questions about standard background-check practices and employer due diligence in biotech and pharmaceutical hiring. Specifically, observers and reporters asked how an individual could evade scrutiny for so long and why multiple employers did not uncover the criminal history or the alleged fabrications earlier. The account noted industry recruiters found the fictional CV plausible because it checked the typical boxes sought for senior roles.
Another item in the roundup summarizes a legal filing by Mary Hitchcock Memorial Hospital in New Hampshire challenging a policy announced by Eli Lilly. The hospital’s lawsuit alleges that Lilly’s new requirement — that certain hospitals submit claims data when dispensing the company’s drugs under the federal 340B drug discount program — imposes illegal, non-negotiable terms and functions as an effort to extract commercially valuable data.
Mary Hitchcock Memorial Hospital says it refused to comply with Lilly’s February announcement and that the company has reacted by terminating discounts to dozens of hospitals. The hospital characterizes Lilly’s approach as involving “non-negotiable terms” and “retaliatory pricing penalties,” according to the reporting the column cites. The legal filing linked in the coverage frames the dispute as a challenge to the scope and legality of Lilly’s data-demand policy.
This development places contractual interactions between manufacturers and 340B-participating hospitals under scrutiny, highlighting tensions over data access, pricing practices, and the leverage manufacturers may exert when modifying discount arrangements.
The roundup header references a separate judicial development: a U.S. court dismissed AstraZeneca’s attempt to block a Maine law that regulates drugmaker contracts with pharmacies. The article provides this as a brief news point; no additional details of the court’s reasoning or the provisions of the Maine law are provided in the excerpted coverage.
Readers should note that the source material cited this legal outcome as one item among several industry-legal stories, underscoring ongoing litigation and regulatory friction between manufacturers, states, and other health-system stakeholders.
Some portions of the Pharmalot column and linked, expanded reporting are marked exclusive to STAT+ subscribers. The column includes a paywall notice indicating that full access to the in-depth reporting requires a STAT+ subscription or logging in. The roundup itself synthesizes reporting from STAT and other outlets but directs readers to premium content for extended analysis and documents such as the hospital lawsuit.
If readers seek the underlying court filings, full investigative pieces, or the complete STAT reporting referenced here, those documents and longer-form articles are subject to STAT+ access rules as noted in the column.
Note: All facts in this summary and rewrite are taken from the provided STAT Pharmalot column excerpt and the linked summaries it cites. Where the source did not provide further factual detail — for example, specific court reasoning in the AstraZeneca matter or detailed contractual language from Lilly — those details were not reported in the source and are not asserted here.